摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-succinimidyl monosuccinate | 102696-21-9

中文名称
——
中文别名
——
英文名称
N-succinimidyl monosuccinate
英文别名
succinimidyl diester of succinic acid;bis-hydroxysuccinimide succinate;succinimidyl succinate;Butanoic acid, 4-[(2,5-dioxo-1-pyrrolidinyl)oxy]-4-oxo-;4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid
N-succinimidyl monosuccinate化学式
CAS
102696-21-9
化学式
C8H9NO6
mdl
——
分子量
215.163
InChiKey
QXZGLTYKKZKGLN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    400.6±47.0 °C(Predicted)
  • 密度:
    1.52±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.3
  • 重原子数:
    15
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    101
  • 氢给体数:
    1
  • 氢受体数:
    6

SDS

SDS:033c90a2e3e9e9e1b43380bf5b2615b9
查看

反应信息

  • 作为反应物:
    描述:
    N-succinimidyl monosuccinate氯化亚砜 作用下, 反应 3.0h, 以91%的产率得到N-succinimidyl 3-(chlorocarbonyl) propanoate
    参考文献:
    名称:
    Charbonnel-Jobic, Gaelle; Guemas, Jean-Pierre; Adelaere, Bruno, Bulletin de la Societe Chimique de France, 1995, vol. 132, p. 624 - 636
    摘要:
    DOI:
  • 作为产物:
    参考文献:
    名称:
    [EN] COVALENTLY COATED ADENO-ASSOCIATED VIRUS VECTOR FOR ITS USE IN GENE THERAPY
    [FR] VECTEUR DE VIRUS ADÉNO-ASSOCIÉ REVÊTU DE MANIÈRE COVALENTE POUR SON UTILISATION EN THÉRAPIE GÉNIQUE
    摘要:
    It is provided an adeno-associated virus (AAV) vector particle, wherein the AAV has at least one capsid protein having one N-terminal covalently bond to a poly(beta aminoester) (PBAE), or a pharmaceutically acceptable salt thereof. It is also provided a pharmaceutical composition of the AAV vector particle, an acid activated PBAE, and an acid activated oligopeptide modified PBAE (OM-PBAE).
    公开号:
    WO2023006651A1
点击查看最新优质反应信息

文献信息

  • Macrocyclic compounds as inhibitors of viral replication
    申请人:Blatt M. Lawrence
    公开号:US20050267018A1
    公开(公告)日:2005-12-01
    The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    该实施例提供了一般式I-XIX的化合物,以及包括药物组合在内的组合物,其中包括一种主体化合物。该实施例还提供了治疗方法,包括治疗黄病毒感染的方法,包括丙型肝炎病毒感染的方法和治疗肝纤维化的方法,这些方法通常涉及向需要的个体施用一种主体化合物或组合物的有效量。
  • POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY
    申请人:Wu Nian
    公开号:US20150157721A1
    公开(公告)日:2015-06-11
    The invention comprises compounds, methods of making, and methods of using. The compounds may have a linear or cylic backbone and three or four appended functional groups: one or two lipohilic compounds including sterols or “fat soluble” vitamins, one or two hydrophilic polymer, and one or two carbohydrate. A group of polymer-carbohydrate conjugates having a central backbone and three appended functional groups are disclosed wherein one lipophilic compound is void of both steroid acids. The conjugate may have fatty acids as the primary lipophilic carrier, one hydrophilic polymer, and one carbohydrate. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. Typical coupling reaction of the conjugates may involve one or more or combinations or in series of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. A variety of linkers between the backbone and functional groups may also be selected to modify the carriers or center backbones for the coupling reactions and optimize performance of the conjugates.
    该发明包括化合物、制备方法和使用方法。这些化合物可能具有线性或环状的骨架,以及三个或四个附加的功能基团:一个或两个疏水化合物,包括固醇或“脂溶性”维生素,一个或两个亲水性聚合物,以及一个或两个碳水化合物。公开了一组具有中心骨架和三个附加功能基团的聚合物-碳水化合物共轭物,其中一个疏水性化合物不含类固醇酸。该共轭物可能以脂肪酸作为主要疏水载体,一个亲水性聚合物和一个碳水化合物。特定的功能基团可以根据在制备药物、化妆品、营养保健品等方面的具体应用而选择。共轭物的典型偶联反应可能涉及一种或多种或组合或串联的烷基化,包括N-烷基化或O-烷基化,醚化,酯化和酰胺化化学过程。还可以选择各种连接剂连接骨架和功能基团之间,以修改载体或中心骨架以进行偶联反应并优化共轭物的性能。
  • Modified Human Apolipoprotein A-1 and Their Uses
    申请人:Knudsen Nick
    公开号:US20110178029A1
    公开(公告)日:2011-07-21
    Modified human apolipoprotein A-I polypeptides and uses thereof are provided.
    提供了改良的人类载脂蛋白A-I多肽及其用途。
  • MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES
    申请人:KRAYNOV Vadim
    公开号:US20120046229A1
    公开(公告)日:2012-02-23
    Modified relaxin polypeptides and their uses thereof are provided
    修改后的弛缓素多肽及其用途
  • Modified Leptin Polypeptides and Their Uses
    申请人:Kraynov Vadim
    公开号:US20120149636A1
    公开(公告)日:2012-06-14
    Modified human leptin polypeptides and uses thereof are provided.
    提供了改良的人类瘦素多肽及其用途。
查看更多